Stemline Therapeutics, Inc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematologic malignancy with both bone marrow and cutaneous manifestations and is derived from plasmacytoid dendritic cells. BPDCN has a poor prognosis and a median overall survival of approximately 12 months. There are no currently approved treatment options. BPDCN has a unique diagnostic signature–CD123/CD4/CD56–that can be used to correctly diagnose, and prevent misdiagnosis, thereby guiding proper treatment selection.